Skip to main content

Life Sciences

From "Go" to "Go Public" and Beyond

We breathed life into the life sciences industry. The 1970s saw not only the emergence of the biotech sector, but also the emergence of Mintz as a leading law firm to the life sciences industry. We grew our capabilities in unison with the expansion of legal and business challenges facing industry companies.

Today, almost 50 years later, we have more than 150 practitioners providing a full spectrum of industry-specific business and litigation representation. 

View our report on M&A activity in the life sciences, produced in conjunction with MergerMarket.

Seizing Oppotunity: The Post-Pandemic Future of Life Sciences M&A

Sign up for insights

Share Awards

Our Experience

Case Study
Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.
$43B+ in transactions since 2020

including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings

Case Study
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.

Areas of Focus

Our Approach

Our roster of industry clients includes start-ups seeking their first funding and large public companies with products on the market. Venture capital firms and investment banks. And research and academic institutions. The services we provide to these clients are as varied as their challenges. Our integrated IP, regulatory, litigation, and corporate practice addresses all of their legal needs. 

Mintz's reputation for excellence in the life sciences has made us the law firm of choice for investment banks including Citi, Cowen, Stifel, HC Wainwright, and Canaccord.  

  • IPOs, follow-on offerings, and PIPE transactions
  • Reverse mergers, Form 10s, and APOs
  • Securities regulatory compliance and corporate governance advice
  • M&As
  • Strategic collaborations and licensing
  • Angel and venture capital financing
  • Equity compensation
Intellectual Property
  • Patent prosecution and strategy
  • Patent infringement litigation
  • Hatch-Waxman Paragraph IV litigation
  • Alternative dispute resolution
  • Trademark strategy and registration
  • Trade Secrets
Compliance & Regulation
  • FDA regulatory counseling
  • Clinical trials
  • Compliance planning
  • Health care fraud and abuse
  • Reimbursement
  • Partnership and JV Disputes
  • Arbitration and Mediation
  • Securities
  • Products Liability
  • Patent Infringement
  • Trade Secrets
  • Contracts

MintzEdge: A resource for entrepreneurs

Insights and tools for starting or growing your enterprise.

What Our Clients Are Saying

Meet Mintz